Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 406-410

  Galsky, M D ^a   Chen, G J ^b   Oh, W K ^a   Bellmunt, J ^c   Roth, B J ^d   Petrioli, R ^e   Dogliotti, L ^f   Dreicer, R ^g   Sonpavde, G ^b,h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF SIENA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g LERNER RESEARCH INSTITUTE   (United States)

^h TEXAS ONCOLOGY   (United States)

Author keywords

Bladder cancer; Carboplatin; Chemotherapy; Cisplatin; Meta analysis; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; META ANALYSIS; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

EID: 84863011634     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr156     Document Type: Article

References (23)

1. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-228.
2. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100: 1639-1645.
3. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
4. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19: 2638-2646.
5. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
6. Galsky MD, Iasonos A, Mironov S et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109: 549-555.
7. Bamias A, Moulopoulos LA, Koutras A et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006; 106: 297-303.
8. Carles J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol 2001; 28: 19-24.
9. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-2533.
10. Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998; 16: 1844-1848.
11. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513.
12. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009; 27: 5634-5639.
13. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-1972.
14. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52: 134-141.
15. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatincontaining regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 344-351.
16. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
17. Van Oosterom AT, Akaza H, Hall R et al. Response criteria phase II/phase III invasive bladder cancer. Prog Clin Biol Res 1986; 221: 301-310.
18. Cooper H, Hedges L. The Handbook of Research Synthesis. New York: Russell Sage 1994.
19. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181.
20. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876-2881.
21. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921-1927.
22. Stadler WM, Hayden A, von der Maase H et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002; 7: 153-157.
23. von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999; 10: 1461-1465.